Table 4.

ANOVA with repeated measures within subjects at posttreatment and 12-month follow-up (the total sample)

Instrument	Assessment	N	M	SD	df	F
BPRS overall	Pre	27	50.06	9.67
	Post	27	44.91	9.36	(1,26)	11.77**
	12-month	27	46.36	11.02	(1,26)	3.72
SANS global	Pre	27	7.48	3.59
	Post	27	6.19	3.41	(1,26)	3.21
	12-month	27	7.59	3.63	(1,26)	0.03
GAF symptom	Pre	26	36.62	4.89
	Post	26	42.92	8.48	(1,25)	17.32***
	12-month	26	41.42	6.96	(1,25)	9.50**
GAF function	Pre	26	42.23	9.47
	Post	26	44.58	9.57	(1,25)	1.13
	12-month	26	45.88	9.99	(1,25)	3.06
PSYRATS AH
Physical	Pre	28	5.82	4.71
	Post	28	5.21	4.92	(1,27)	2.31
	12-month	28	5.44	4.82	(1,27)	0.43
Emotional	Pre	28	6.61	5.51
	Post	28	5.21	5.13	(1,27)	6.53*
	12-month	28	5.54	5.36	(1,27)	2.58
Cognitive	Pre	28	4.84	3.99
	Post	28	4.05	3.96	(1,27)	2.31
	12-month	28	4.25	3.82	(1,27)	1.38
PSYRATS D
Cognitive	Pre	26	6.85	5.00	(1,25)
	Post	26	4.38	4.67	(1,25)	8.41**
	12-month	26	5.50	4.70	(1,25)	2.62
Emotional	Pre	26	3.27	2.88
	Post	26	1.85	2.34	(1,25)	5.10*
	12-month	26	2.58	2.66	(1,25)	1.63

Notes: *** = Significant level 0.001; ** = Significant level 0.01; * = Significant level 0.05.